These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 2445293)
1. [Significance of tumor markers in the treatment of patients with ovarian malignancies]. Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293 [TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin. Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639 [TBL] [Abstract][Full Text] [Related]
3. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers]. Kataoka A; Yakushiji M Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors]. Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of tumor markers in patients with colorectal cancer]. Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727 [TBL] [Abstract][Full Text] [Related]
6. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers]. Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877 [TBL] [Abstract][Full Text] [Related]
7. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers]. Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666 [TBL] [Abstract][Full Text] [Related]
8. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms]. Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349 [TBL] [Abstract][Full Text] [Related]
9. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer]. Lahousen M Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273 [TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary]. Chen C; Li JD; Huang H; Feng YL; Wang LH; Chen L Ai Zheng; 2008 Jan; 27(1):92-5. PubMed ID: 18184473 [TBL] [Abstract][Full Text] [Related]
11. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer]. Paulick R; Kaesemann H; Caffier H Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919 [TBL] [Abstract][Full Text] [Related]
12. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance]. Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032 [TBL] [Abstract][Full Text] [Related]
13. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294 [TBL] [Abstract][Full Text] [Related]
14. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary]. Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097 [TBL] [Abstract][Full Text] [Related]
15. [The clinical value of tissue polypeptide antigen in ovarian carcinoma]. Wu L; Sun J; Wang X Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428 [TBL] [Abstract][Full Text] [Related]
16. [Changes in serum levels of gynecological tumor markers throughout the period from early gestation to puerperium]. Sugawara T; Tanaka T; Sato H; Hanatani K; Okuyama K; Shinkai N; Sakuragi N; Makinoda S; Fujimoto S Nihon Sanka Fujinka Gakkai Zasshi; 1991 Feb; 43(2):145-51. PubMed ID: 1707431 [TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of tumor markers in breast cancer patients]. Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907 [TBL] [Abstract][Full Text] [Related]
18. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance. Gebauer G; Müller-Ruchholtz W Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706 [TBL] [Abstract][Full Text] [Related]
19. [Tumor marker combination versus second-look operation in ovarian cancer]. Lahousen M; Stettner H; Pürstner P; Pickel H Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187 [TBL] [Abstract][Full Text] [Related]
20. [Significance of serum ferritin level in testicular tumors]. Takai K; Kojima H; Kume H; Takemura T; Moriyama N; Murahashi I; Aso Y Hinyokika Kiyo; 1991 Apr; 37(4):357-62. PubMed ID: 1716405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]